0 CHECKOUT

Erectile Dysfunction - Pipeline Review, H2 2015

  • ID: 3387848
  • July 2015
  • Region: Global
  • 113 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Acorda Therapeutics, Inc.
  • Aprogen, Inc.
  • Futura Medical Plc
  • Mezzion Pharma Co. Ltd.
  • NAL Pharmaceuticals Ltd.
  • Pharmicell Co., Ltd.
  • MORE

Erectile Dysfunction - Pipeline Review, H2 2015

Summary

The report ‘Erectile Dysfunction - Pipeline Review, H2 2015’, provides an overview of the Erectile Dysfunction’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Erectile Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Erectile Dysfunction and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Acorda Therapeutics, Inc.
  • Aprogen, Inc.
  • Futura Medical Plc
  • Mezzion Pharma Co. Ltd.
  • NAL Pharmaceuticals Ltd.
  • Pharmicell Co., Ltd.
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Erectile Dysfunction Overview
Therapeutics Development
Pipeline Products for Erectile Dysfunction - Overview
Pipeline Products for Erectile Dysfunction - Comparative Analysis
Erectile Dysfunction - Therapeutics under Development by Companies
Erectile Dysfunction - Therapeutics under Investigation by Universities/Institutes
Erectile Dysfunction - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Erectile Dysfunction - Products under Development by Companies
Erectile Dysfunction - Products under Investigation by Universities/Institutes
Erectile Dysfunction - Companies Involved in Therapeutics Development
Acorda Therapeutics, Inc.
Apricus Biosciences, Inc.
Aprogen, Inc.
Bioheart, Inc.
Biolab Sanus Farmaceutica Ltda.
Corridor Pharmaceuticals Inc.
Futura Medical Plc
Hanmi Pharmaceuticals, Co. Ltd.
IntelGenx Corp.
Mezzion Pharma Co. Ltd.
Mitsubishi Tanabe Pharma Corporation
Monosol Rx, LLC
NAL Pharmaceuticals Ltd.
Pacific Therapeutics Ltd.
Palatin Technologies, Inc.
Pharmicell Co., Ltd.
Sagene Pharmaceuticals, Inc.
Suda Ltd
Yungjin Pharm Ind. Co., Ltd.
Erectile Dysfunction - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(tramadol hydrochloride + PDE-5 Inhibitor) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AdipoCell - Drug Profile
Product Description
Mechanism of Action
R&D Progress
alprostadil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AP-102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
avanafil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BL-214 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cimaglermin alfa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HCP-1302 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HCP-1303 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Immpocellgram - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MED-2003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MED-2004 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MED-2005 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
nitroglycerin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Drug Profile
Product Description
Mechanism of Action
R&D Progress
selegiline + PDE-5 Inhibitor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sildenafil citrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sildenafil citrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sildenafil citrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sildenafil citrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit Arginase for Vascular Dysfunction, PAH and Erectile Dysfunction - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptide to Agonize Melanocortin 4 Receptor for Female Sexual Dysfunction and Erectile Dysfunction - Drug Profile
Product Description
Mechanism of Action
R&D Progress
T-6932 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tadalafil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tadalafil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tadalafil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TPN-171 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TPN-729 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TR-399 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
udenafil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VLFIA-330 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
YBH-1603 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Erectile Dysfunction - Recent Pipeline Updates
Erectile Dysfunction - Dormant Projects
Erectile Dysfunction - Discontinued Products
Erectile Dysfunction - Product Development Milestones
Featured News & Press Releases
Jan 29, 2015: VIVUS Announces European Approval of SPEDRA Label Amendment; SPEDRA Now First and Only Oral Erectile Dysfunction Treatment Approved in Europe to Be Taken Approximately 15 Minutes Before Sexual Activity
Nov 20, 2014: Auxilium Pharmaceuticals Presents STENDRA Data At SMSNA Scientific Meeting
Nov 03, 2014: Auxilium Pharmaceuticals To Present STENDRA Data At SMSNA Scientific Meeting
Sep 18, 2014: VIVUS and Auxilium Announce FDA Approval of STENDRA sNDA; STENDRA Now First and Only Oral Erectile Dysfunction Treatment Approved to Be Taken Approximately 15 Minutes Before Sexual Activity
Apr 11, 2014: VIVUS To Present Clinical Data On Avanafil at European Association of Urology
Feb 24, 2014: IntelGenx Achieves Positive Bioequivalence Results for Erectile Dysfunction VersaFilm Tadalafil Product
Jan 21, 2014: VIVUS and Auxilium Announce FDA Acceptance of Supplemental Filing Seeking an Update of Prescribing Information for STENDRA (avanafil)
Aug 01, 2013: VIVUS Announces Commercial Supply Agreement With Sanofi to Produce Avanafil
Jun 26, 2013: Vivus Announces European Approval For Spedra For Treatment Of Erectile Dysfunction
Jun 19, 2013: Vivus Announces Positive Results From TA-501 Clinical Trial Of Stendra For Treatment Of Men With Erectile Dysfunction
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Erectile Dysfunction, H2 2015
Number of Products under Development for Erectile Dysfunction - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015
Erectile Dysfunction - Pipeline by Acorda Therapeutics, Inc., H2 2015
Erectile Dysfunction - Pipeline by Apricus Biosciences, Inc., H2 2015
Erectile Dysfunction - Pipeline by Aprogen, Inc., H2 2015
Erectile Dysfunction - Pipeline by Bioheart, Inc., H2 2015
Erectile Dysfunction - Pipeline by Biolab Sanus Farmaceutica Ltda., H2 2015
Erectile Dysfunction - Pipeline by Corridor Pharmaceuticals Inc., H2 2015
Erectile Dysfunction - Pipeline by Futura Medical Plc, H2 2015
Erectile Dysfunction - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2015
Erectile Dysfunction - Pipeline by IntelGenx Corp., H2 2015
Erectile Dysfunction - Pipeline by Mezzion Pharma Co. Ltd., H2 2015
Erectile Dysfunction - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2015
Erectile Dysfunction - Pipeline by Monosol Rx, LLC, H2 2015
Erectile Dysfunction - Pipeline by NAL Pharmaceuticals Ltd., H2 2015
Erectile Dysfunction - Pipeline by Pacific Therapeutics Ltd., H2 2015
Erectile Dysfunction - Pipeline by Palatin Technologies, Inc., H2 2015
Erectile Dysfunction - Pipeline by Pharmicell Co., Ltd., H2 2015
Erectile Dysfunction - Pipeline by Sagene Pharmaceuticals, Inc., H2 2015
Erectile Dysfunction - Pipeline by Suda Ltd, H2 2015
Erectile Dysfunction - Pipeline by Yungjin Pharm Ind. Co., Ltd., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Erectile Dysfunction Therapeutics - Recent Pipeline Updates, H2 2015
Erectile Dysfunction - Dormant Projects, H2 2015
Erectile Dysfunction - Dormant Projects (Contd..1), H2 2015
Erectile Dysfunction - Dormant Projects (Contd..2), H2 2015
Erectile Dysfunction - Discontinued Products, H2 2015

List of Figures
Number of Products under Development for Erectile Dysfunction, H2 2015
Number of Products under Development for Erectile Dysfunction - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

- Acorda Therapeutics, Inc.
- Apricus Biosciences, Inc.
- Aprogen, Inc.
- Bioheart, Inc.
- Biolab Sanus Farmaceutica Ltda.
- Corridor Pharmaceuticals Inc.
- Futura Medical Plc
- Hanmi Pharmaceuticals, Co. Ltd.
- IntelGenx Corp.
- Mezzion Pharma Co. Ltd.
- Mitsubishi Tanabe Pharma Corporation
- Monosol Rx, LLC
- NAL Pharmaceuticals Ltd.
- Pacific Therapeutics Ltd.
- Palatin Technologies, Inc.
- Pharmicell Co., Ltd.
- Sagene Pharmaceuticals, Inc.
- Suda Ltd
- Yungjin Pharm Ind. Co., Ltd.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Pfizer Inc.
  • Grünenthal GmbH
  • GlaxoSmithKline PLC
  • Abbott Laboratories Ltd.
  • Roche Diagnostics Ltd.
  • Novo Nordisk A/S